Janux Therapeutics Inc Forecast, price target & analysts
Janux Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Janux Therapeutics Inc Classifications & Recommendation:
Janux Therapeutics Inc Price Target
| Target Price | $90.67 |
| Price | $32.01 |
| Potential |
183.25%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Janux Therapeutics Inc 2026 .
The average Janux Therapeutics Inc target price is $90.67.
This is
183.25%
register free of charge
$200.00
524.80%
register free of charge
$25.00
21.90%
register free of charge
|
|
| A rating was issued by 15 analysts: 13 Analysts recommend Janux Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2026 of
183.25%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 8.08 | 10.99 |
| 6.16% | 36.05% | |
| EBITDA Margin | -878.96% | -932.94% |
| 14.23% | 6.14% | |
| Net Margin | -855.06% | -644.54% |
| 7.46% | 24.62% |
12 Analysts have issued a sales forecast Janux Therapeutics Inc 2024 . The average Janux Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Janux Therapeutics Inc 2024 . The average Janux Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Janux Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Janux Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.32 | -1.35 |
| 13.16% | 2.27% | |
| P/E | negative | |
| EV/Sales | 113.68 |
8 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Janux Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Janux Therapeutics Inc...
Current Janux Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Dec 11 2024 |
| Scotiabank | Locked ➜ Locked | Locked | Dec 04 2024 |
| Stifel | Locked ➜ Locked | Locked | Dec 03 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 03 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Dec 03 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Nov 22 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
Stifel: Locked ➜ Locked
|
Dec 03 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 03 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Dec 03 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Nov 22 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
